002210.KO Dong Sung Bio Pharm.Co.,Ltd.
- Market cap
- KRW 105B
- P/E
- 62.9x
- P/B
- 1.22x
- ROE
- -13.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 002210.KO undervalued?
Graham number002210.KO trades 85.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dong Sung Bio Pharm.Co.,Ltd. fundamental analysis
No fundamental analysis for Dong Sung Bio Pharm.Co.,Ltd. yet.
Dong Sung Bio Pharm.Co.,Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dong Sung Bio Pharm.Co.,Ltd.
Dong Sung Bio Pharm.Co.,Ltd. manufactures and sells pharmaceuticals and cosmetics in South Korea. The company offers over the counter drugs, such as emollient, vitamin supplement, alopecia treatment, antihistamines, liver disease treatment, fire extinguisher solvent, antiviral, eye drops, menopause treatment, sleep inducer, antipyretic, analgesic, anti-inflammatory, vascular reinforcement, broad-spectrum skin disease treatment, gum disease treatment, blood circulation improv…
Full company profileDong Sung Bio Pharm.Co.,Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dong Sung Bio Pharm.Co.,Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 79.7B | 82.4B | 91.9B | 86.5B | 87.8B | 84.4B | 93.3B | 88.6B | 88.4B | 87.2B | 82.4B |
| Gross Profit | 37.1B | 36.1B | 35.2B | 33.1B | 34.1B | 33.5B | 42.1B | 41.4B | 38.8B | 37.1B | 34.8B |
| Operating Income | -2.29B | 955M | -1.81B | -7.53B | -3.67B | -5.30B | -3.10B | 665M | -5.73B | -10.1B | -3.49B |
| EBITDA | - | 2.71B | -3.02B | -5.25B | -7.86B | -1.44B | 1.58B | -416M | -9.20B | -16.8B | -8.80B |
| Net Income | -1.66B | -198M | -5.74B | -8.39B | -14.1B | -4.31B | -2.12B | -5.97B | -14.6B | -25.7B | -11.8B |
| EPS | - | -8.90 | -258 | -355 | -601 | -187 | -93 | -261 | -637 | -1,054 | -122 |
| Balance Sheet | |||||||||||
| Total Assets | 125B | 124B | 140B | 132B | 126B | 105B | 108B | 111B | 141B | 168B | 160B |
| Total Liabilities | 69.8B | 59.9B | 82.7B | 61.6B | 70.8B | 58.1B | 64.9B | 75.1B | 96.7B | 145B | 72.3B |
| Shareholders' Equity | 55.6B | 64.3B | 57.5B | 70.1B | 54.9B | 46.4B | 42.8B | 35.9B | 44.0B | 23.4B | 87.5B |
| Cash & Short-term Investments | 2.91B | 4.05B | 2.21B | 4.28B | 14.4B | 3.14B | 4.09B | 6.44B | 3.15B | 3.86B | 37.5B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.34B | 1.80B | 1.39B | -8.31B | 5.01B | -2.75B | -3.88B | -6.29B | -14.8B | -12.9B | -39.4B |
| Capital Expenditure | 2.84B | 3.00B | 2.13B | 1.42B | 6.92B | 2.32B | 643M | 924M | 2.47B | 1.34B | 1.26B |
| Free Cash Flow | - | -1.21B | -734M | -9.73B | -1.91B | -5.08B | -4.53B | -7.22B | -17.3B | -14.2B | -40.6B |
| Ratios | |||||||||||
| ROE | -3.0% | -0.3% | -10.0% | -12.0% | -25.6% | -9.3% | -5.0% | -16.6% | -33.1% | -110.1% | -13.4% |
| ROA | -1.3% | -0.2% | -4.1% | -6.4% | -11.2% | -4.1% | -2.0% | -5.4% | -10.4% | -15.3% | -7.4% |
| Net Profit Margin | -2.1% | -0.2% | -6.3% | -9.7% | -16.0% | -5.1% | -2.3% | -6.7% | -16.5% | -29.5% | -14.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Dong Sung Bio Pharm.Co.,Ltd. dividends
Dong Sung Bio Pharm.Co.,Ltd. has not paid dividends in the last 9 fiscal years.
Last stock split: 5:1 on Dec 22, 2008.
Who owns Dong Sung Bio Pharm.Co.,Ltd.
- Insiders 75.73%
- Institutions 0.01%
- Public & others 24.27%
- Shares outstanding 94.2M
- Free float 9.84M
Dong Sung Bio Pharm.Co.,Ltd. company profile
- Company name
- Dong Sung Bio Pharm.Co.,Ltd.
- Ticker
- 002210.KO
- ISIN
- KR7002210003
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 298
- Fiscal year end
- December
- Address
- Dongsung Building, Seoul, South Korea, 01340
- Phone
- 82 2 6911 3600
- Website
- dongsung-pharm.com
About Dong Sung Bio Pharm.Co.,Ltd.
Dong Sung Bio Pharm.Co.,Ltd. manufactures and sells pharmaceuticals and cosmetics in South Korea. The company offers over the counter drugs, such as emollient, vitamin supplement, alopecia treatment, antihistamines, liver disease treatment, fire extinguisher solvent, antiviral, eye drops, menopause treatment, sleep inducer, antipyretic, analgesic, anti-inflammatory, vascular reinforcement, broad-spectrum skin disease treatment, gum disease treatment, blood circulation improver, scar treatment, dry stomach, eye nourishment, abdominal obesity treatment, anti-soil agent, respiratory solvent, and antifungal agent. It also provides prescription drugs, including endocrine system, corticosteroids, fire extinguishing system, circulatory system, psychotropic solvents, tumor therapy, analgesic anti-inflammatory, cutaneous urinary system, antiviral, antibiotics, and respiratory system. In addition, the company offers hair dye, cosmetics, health functional supplements, nasal spray, household goods, muscle taping, disinfectant, toothpaste, anti-hair loss shampoo, and sanitary napkin. The company was founded in 1957 and is headquartered in Seoul, South Korea.
Dong Sung Bio Pharm.Co.,Ltd. management
4- Mr. Won-gyun NaChairman & CEO · born 1986
- Ms. Young-ja OhManaging Director · born 1961
- Mr. Cheol-woo KimManaging Director · born 1965
- Mr. Sang-hyeon ParkManaging Director · born 1967